Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Atomoxetine (Strattera, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far, two open-label and seven randomised, double-blind, placebo-controlled, clinical trials have been published, six in youths and three in adults. Each of these trials has shown a positive response as measured by the primary efficacy measures, the ADHD-IV Rating Scale (ADHD RS) or the Conners Adult ADHD Rating Scale (CAARS). Atomoxetine has generally been well tolerated. In November of 2002 the FDA approved atomoxetine for use in the US for the treatment of ADHD in children, adolescents and adults. Atomoxetine is the first nonstimulant approved by the FDA for the treatment of ADHD and the first medication approved for the treatment of adult ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“Of the 19 atomoxetine subjects who reported nausea or vomiting, the symptoms were generally transient, with 16 of these subjects completing the trial and enrolling in an open-label extension study of atomoxetine so as to continue receiving the medication [27].”
BackgroundSelf-citationSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 3×
“4 Double-blind, placebo-controlled efficacy trials of atomoxetine Two identical multi-centre (17 sites), double-blind, placebocontrolled trials were conducted in children 7 – 13 years of age [23].”
BackgroundInfluentialSelf-citationMedication treatment strategies in the MTA Study: relevance to clinicians and researchers
GREENHILL, L. L., ABIKOFF, H. B., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., ELLIOTT, G., HECHTMAN, L., HINSHAW, S. P., HOZA, B., JENSEN, P. S., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00017 · Cited by 297
KRATOCHVIL, C. J., HEILIGENSTEIN, J. H., DITTMANN, R., SPENCER, T. J., BIEDERMAN, J., WERNICKE, J., NEWCORN, J. H., CASAT, C., MILTON, D., & MICHELSON, D. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200207000-00008 · Cited by 292 · cited 3×
“Nonetheless, the data provides preliminary evidence suggesting that atomoxetine might be associated with therapeutic effects comparable to those observed with methylphenidate, and with similar safety and tolerability [21].”
BackgroundResultSelf-citationA Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272 · cited 1×
“Bupropion has demonstrated efficacy in several trials in the treatment of children and adults with ADHD [13,14], and is often used by clinicians as a second-line treatment for ADHD.”
Background
Cited by
sagvolden, T., johansen, E. B., aase, H., & russell, V. A. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000075 · Cited by 1,035
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359
“The evaluation of ADHD medications using animal ‘models’ is not straightforward, since ADHD typically presents as a spectrum of disorders, and no animal ‘models’ replicate the full range of deficits found in ADHD (for discussion see Sagvolden et al, 2005; Russell et al, 2005).”
BackgroundInfluentialA Systematic Review of Modafinil: Potential Clinical Uses and Mechanisms of Action
Ballon, J. S., & Feifel, D. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0406 · Cited by 349
Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence
Brown, R. T., Amler, R. W., Freeman, W. S., Perrin, J. M., Stein, M. T., Feldman, H. M., Pierce, K., Wolraich, M. L., & and the Committee on Quality Improvement, S. O. A.-D. D. (2005) · Pediatrics · doi:10.1542/peds.2004-2560 · Cited by 330
Metadata
- Authors
- Kratochvil, C. J., Vaughan, B. S., Harrington, M. J., & Burke, W. J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2003-07
- Volume
- 4
- Issue
- 7
- Pages
- 1165-1174
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2101565436
- Cited by
- 94
- References
- 11
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. https://app.cochat.ai/papers/10.1517/14656566.4.7.1165
- The paper
- Kratochvil, C. J., Vaughan, B. S., Harrington, M. J., & Burke, W. J. (2003). Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.4.7.1165
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.